INTS News

Seven issuers began trading in the final week of June, six of which are eligible for inclusion in our IPO stats and four of which raised $100+ million. They were joined by one blank check company. The 2Q saw the IPO market end with much more momentum than it began. For detailed discussion of activity over the past quarter and what it means for the second half of the year, read our...read more

Intensity Therapeutics, a Phase 2 biotech developing intratumoral injection therapies for cancer, raised $20 million by offering 3.9 million shares at $5, the high end of the range of $4 to $5. The company offered 0.7 million more shares than anticipated. Intensity Therapeutics originally filed for an IPO in October 2021 and set terms the following November, planning to offer 1.5...read more

Intensity Therapeutics, a Phase 2 biotech developing intratumoral injection therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. In its latest filing, the company also disclosed financials for the three months ended March 31, 2023, and added Freedom Capital Markets as an underwriter. Intensity Therapeutics now plans to raise $15 million by offering...read more

Two small issuers began trading this past week, only one of which was large enough to be included in our IPO stats, as several deals postponed (SODR, MGRX) or delayed (TRNR, INTS, NRXS). Two SPACs also priced. Eight IPOs submitted initial filings, the largest of which plans to raise just $29 million, as well as one SPAC. The most notable news came from the pipeline, with...read more